Clinical Trials

Provision Center for Biomedical Research serves as an independent research site, consistently delivering excellence in patient care and study performance that meets research requirements and builds strong relationships with physician and sponsor partners.

Listed below are Active and Upcoming Clinical Trials. “Active” status means that Provision Center for Biomedical Research is actively involved in the trial, which may or may not be accepting new patients. Active status has two types: “Active: Open to Patient Enrollment” status is in the patient recruitment phase, where patients are welcome to enroll, provided they meet the study criteria; or “Active: Closed to Patient Enrollment”, where the study is still active in collecting data, but is closed to enrolling new patients. Should patients be interested in a trial that is closed to enrollment, they may inquire about other studies where they might qualify to participate.

If you would like more information on our clinical trials or want to learn more about enrollment, please CONTACT US

Active and Upcoming Clinical Trials

Listing Category
Description

A phase 3, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833), a next generation. Oral selective estrogen receptor degrader, versus standard endocrine therapy, as adjusted treatment for patients with ER+/HER2- early breast cancer and an intermediate -high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence or disease

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Robert Schumaker, Tennessee Cancer Specialists
Listing Title
Listing Category
Description


PHINDER: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Eric Weaver, StatCare Medical Group
Listing Title
Listing Category
Description

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Robert Schumaker, Tennessee Cancer Specialists
Listing Title
Description


A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of MK-5475 in Adults with pulmonary Arterial Hypertension

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. John Swisher, StatCare Medical Group
Listing Category
Description

An Open label, Multicenter, Phase 1b/2a Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of the ATR inhibitor M1774 in Combination with Cemiplimab in Participants with Non-Squamous Non-Small Cell Lung Cancer that has Progressed on Prior Anti-PD-(L)1 and Platinum-based Therapies.

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Tracy Dobbs, Tennessee Cancer Specialists
Listing Category
Description


A randomized, double blinded, dose ranging, placebo-controlled, phase 2b study to evaluate the efficacy and safety of PLN-74809 (bexategrast) for the treatment of idiopathic pulmonary fibrosis (IPF)

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Eric Weaver, StatCare Medical Group
Listing Title
Listing Category
Description


A randomized, double-blinded, placebo-controlled, phase 3 study of the efficacy and safety of inhaled Treprostinil in subjects with idiopathic pulmonary fibrosis

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Eric Weaver, StatCare Medical Group
Listing Category
Description


An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Eric Weaver, StatCare Medical Group
Listing Category
Description


A randomized, double-blinded, placebo-controlled, multinational, phase 3 study of the efficacy and safety of inhaled Treprostinil in subjects with progressive pulmonary fibrosis

Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Eric Weaver, StatCare Medical Group
Scroll to Top